Top

Current Osteoporosis Reports

Published in:

Open Access 01-03-2010 | CLINICAL TRIAL REPORT

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer

Author: David S. Silver

Published in: Current Osteoporosis Reports | Issue 1/2010

Excerpt

Trial …

Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948–955.CrossRefPubMed

Michaelson MD, Kaufman DS, Lee H, et al.: Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038–1042.CrossRefPubMed

Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008–2012.CrossRefPubMed

Greenspan SL, Nelson JB, Trump DL, Resnick NM: Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416–424.PubMed

Smith MR, Fallon MA, Lee H, Finkelstein HS: Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:3841–3846.CrossRefPubMed

Fizazi K, Lipton A, Mariette X, et al.: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, and other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1564–1571.CrossRefPubMed

Title: Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer
Author: David S. Silver
Publication date: 01-03-2010
Publisher: Current Science Inc.
Published in: Current Osteoporosis Reports / Issue 1/2010
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-010-0001-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Intravenous Zoledronic Acid: What Are the Indications for Male Osteoporosis?

Benefits and Limitations of Bone Mineral Density and Bone Turnover Markers to Monitor Patients Treated for Osteoporosis

Orthopedic Uses of Teriparatide

The Role of Microbial Biofilms in Osteonecrosis of the Jaw Associated with Bisphosphonate Therapy

Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates

Is Osteoporosis Disease Management Cost Effective?